Clinical trial
Combined Exercise and Protein Supplementation to Preserve Skeletal Muscle During GLP-1 Receptor Agonist Treatment in People With Type 2 Diabetes: A Randomized Controlled Multicenter Trial
NCT07926152 is registered in ClinicalTrials.gov with German Diabetes Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Combined Exercise and Protein Supplementation to Preserve Skeletal Muscle During GLP-1 Receptor Agonist Treatment in People With Type 2 Diabetes: A Randomized Controlled Multicenter Trial
- Lead sponsor
- German Diabetes Center
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- February 1, 2027
- Completion date
- January 31, 2030
- Enrollment
- 94 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
obesity & overweight, sarcopenia, type 2 diabetes (t2dm)
Arms
As registered; 2 arms.
-
Exercise and Protein Supplementation
Participants continue their GLP-1 receptor agonist therapy (semaglutide or tirzepatide) as prescribed by their treating physician and receive one standardized lifestyle counselling session on nutrition and physical activity at baseline. In addition, they take part in a 24-week supervised training program with three sessions per week at the study center, alternating between full-body resistance training, high-intensity interval training on a cycle ergometer, and a combined session. Training intensity is progressively increased and individually adjusted. Participants also take 25 g of whey protein isolate daily, directly after each training session or in the morning on training-free days.
-
Usual Care
Participants continue their GLP-1 receptor agonist therapy (semaglutide or tirzepatide) as prescribed by their treating physician and receive one standardized lifestyle counselling session on nutrition and physical activity at baseline. They do not take part in the supervised training program and do not receive protein supplementation.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in Contractile Thigh Muscle Volume
Change in contractile thigh skeletal muscle volume (mL), assessed by magnetic resonance imaging (MRI). Contractile thigh muscle volume is defined as the sum of the bilateral anterior (quadriceps femoris, sartorius, tensor fasciae latae) and posterior (gluteal muscles, iliopsoas, adductors, hamstrings) thigh skeletal muscle volume minus intramuscular adipose tissue (IMAT) volume.
Lead sponsor's other trials
German Diabetes Center, most recent start first.
+25 more trials
Similar trials
Same condition (Sarcopenia) and phase, most recent start first.
+737 more trials See the condition page